[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100404078":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":76,"collaborators":79,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":89,"sex":95,"minAge":10,"maxAge":10,"enrollmentInfo":96,"targetDuration":99,"studyType":100,"phases":10,"briefSummary":101,"conditions":102,"keywords":108,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Variant in the TP53 Gene in blood or saliva",null,"Variant in the TP53 gene found on a blood or saliva test, have a relative with a variant in the TP53 gene, or because participant meets genetic testing criteria for Li-Fraumeni Syndrome (LFS) based on personal or family cancer history",[13],"Genetic: Data and Specimen Collection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"GENETIC","Data and Specimen Collection","* Provide research team and access to relevant medical records\n* Answer short questionnaires periodically\n* Consider consenting to other optional parts of the research such as:\n* Providing up to 3 tubes (15ml) of blood at or near the time of consent, as approved by treating physician (optional).\n* Provide a saliva sample (optional).\n* Provide eyebrow hairs for analysis of DNA from the bulb (15-20 eyebrow plucks) (optional).\n* Provide permission for obtainment of stored tissue specimens from cancer or pre-cancer surgeries or biopsies from the pathology departments where they have been stored (optional).\n* Consider inviting relatives to join the study (optional).",[9],[21],{"name":22,"affiliation":5,"role":23},"Judy E Garber, MD, MPH","PRINCIPAL_INVESTIGATOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","617-632-5770","jegarber@partners.org",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},"Sophie Cahill, BS","617-632-4795","Sophie_Cahill@DFCI.HARVARD.edu",[34,54,65],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Boston Children's Hospital","RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-71.05977,42.35843,{"lat":46,"lon":45},[49,53],{"name":50,"role":26,"phone":51,"phoneExt":10,"email":52},"JUNNE KAMIHARA, MD","888-733-4662","jkamihara@partners.org",{"name":50,"role":23,"phone":10,"phoneExt":10,"email":10},{"facility":55,"status":36,"city":37,"state":38,"zip":56,"country":40,"countryCode":41,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},"Brigham and Women's Hospital","02215",{"type":43,"coordinates":58},[45,46],{"lat":46,"lon":45},[61,64],{"name":62,"role":26,"phone":63,"phoneExt":10,"email":28},"Judy Garber, MD, MPH","617-632-2282",{"name":62,"role":23,"phone":10,"phoneExt":10,"email":10},{"facility":66,"status":36,"city":37,"state":38,"zip":56,"country":40,"countryCode":41,"cosmosGeoPoint":67,"geoPoint":69,"contacts":70},"Judy E. Garber",{"type":43,"coordinates":68},[45,46],{"lat":46,"lon":45},[71,75],{"name":72,"role":26,"phone":73,"phoneExt":10,"email":74},"Judy E. Garber, MD, MPH","617-763-8821","judy_garber@dfci.harvard.edu",{"name":62,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":23,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Judy E. Garber, MD","Principal Investigator",[80,83,85],{"name":81,"class":82},"National Cancer Institute (NCI)","NIH",{"name":84,"class":6},"City of Hope Medical Center",{"name":86,"class":6},"Baylor College of Medicine","100404078","li-fraumeni--tp53-lift-up-understanding-and-progress-100404078",false,"NCT04541654","Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress","Li-Fraumeni & TP53: Understanding and Progress (LiFT UP)","LiFT_UP","Inclusion Criteria:\n\n* Individuals with a TP53 pathogenic or likely pathogenic variant identified in blood or saliva,\n* Individuals with variants of uncertain significance in TP53 may be eligible at the PI's discretion,\n* Blood relatives of individuals with a TP53 variant, who may be presumed obligate carriers or healthy controls,\n* Individuals who meet Classic or Chompret LFS criteria whether or not they have a TP53 gene variant,\n* Individuals may enroll their deceased relatives in the study.\n* Individuals with a known TP53 variant that is not LFS, but rather ACE, CHIP, or mosaicism.\n* Individuals participating in other LFS studies can still enroll in LiFT UP. Investigators may be collaborators.\n\nExclusion Criteria:\n\n* Individuals who decline to sign consent\n* Individuals who are unable to give consent or assent and are without a designated healthcare proxy","ALL",{"count":97,"type":98},1500,"ESTIMATED","5 Years","OBSERVATIONAL","The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE\u002FCHIP and mosaicism).",[103,104,105,106,107],"Li-Fraumeni Syndrome","TP53 Gene Mutation","Hereditary Cancer Syndrome","Clonal Hematopoiesis","Mosaicism",[103,109,105,106,107],"TP53 Gene Mutation (Variant)","2026-03-24",{"date":112,"type":113},"2026-03-27","ACTUAL",{"date":115,"type":113},"2020-09-15",{"date":117,"type":98},"2032-12-31",{"name":5,"class":6},3]